Cargando…
Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients
PURPOSE: The current study aimed to illustrate how a non-linear mixed effect (NLME) model-based analysis may improve confidence in a Phase III trial through more precise estimates of the drug effect. METHODS: The FULFIL clinical trial was a Phase III study that compared 24 weeks of once daily inhale...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314306/ https://www.ncbi.nlm.nih.gov/pubmed/35233731 http://dx.doi.org/10.1007/s11095-022-03194-1 |
_version_ | 1784754290019008512 |
---|---|
author | Llanos-Paez, Carolina Ambery, Claire Yang, Shuying Beerahee, Misba Plan, Elodie L. Karlsson, Mats O. |
author_facet | Llanos-Paez, Carolina Ambery, Claire Yang, Shuying Beerahee, Misba Plan, Elodie L. Karlsson, Mats O. |
author_sort | Llanos-Paez, Carolina |
collection | PubMed |
description | PURPOSE: The current study aimed to illustrate how a non-linear mixed effect (NLME) model-based analysis may improve confidence in a Phase III trial through more precise estimates of the drug effect. METHODS: The FULFIL clinical trial was a Phase III study that compared 24 weeks of once daily inhaled triple therapy with twice daily inhaled dual therapy in patients with chronic obstructive pulmonary disease (COPD). Patient reported outcome data, obtained by using The Evaluating Respiratory Symptoms in COPD (E-RS:COPD) questionnaire, from the FULFIL study were analyzed using an NLME item-based response theory model (IRT). The change from baseline (CFB) in E-RS:COPD total score over 4-week intervals for each treatment arm was obtained using the IRT and compared with published results obtained with a mixed model repeated measures (MMRM) analysis. RESULTS: The IRT included a graded response model characterizing item parameters and a Weibull function combined with an offset function to describe the COPD symptoms-time course in patients receiving either triple therapy (n = 907) or dual therapy (n = 894). The IRT improved precision of the estimated drug effect compared to MMRM, resulting in a sample size of at least 3.64 times larger for the MMRM analysis to achieve the IRT precision in the CFB estimate. CONCLUSION: This study shows the advantage of IRT over MMRM with a direct comparison of the same primary endpoint for the two analyses using the same observed clinical trial data, resulting in an increased confidence in Phase III. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11095-022-03194-1. |
format | Online Article Text |
id | pubmed-9314306 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-93143062022-07-27 Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients Llanos-Paez, Carolina Ambery, Claire Yang, Shuying Beerahee, Misba Plan, Elodie L. Karlsson, Mats O. Pharm Res Original Research Article PURPOSE: The current study aimed to illustrate how a non-linear mixed effect (NLME) model-based analysis may improve confidence in a Phase III trial through more precise estimates of the drug effect. METHODS: The FULFIL clinical trial was a Phase III study that compared 24 weeks of once daily inhaled triple therapy with twice daily inhaled dual therapy in patients with chronic obstructive pulmonary disease (COPD). Patient reported outcome data, obtained by using The Evaluating Respiratory Symptoms in COPD (E-RS:COPD) questionnaire, from the FULFIL study were analyzed using an NLME item-based response theory model (IRT). The change from baseline (CFB) in E-RS:COPD total score over 4-week intervals for each treatment arm was obtained using the IRT and compared with published results obtained with a mixed model repeated measures (MMRM) analysis. RESULTS: The IRT included a graded response model characterizing item parameters and a Weibull function combined with an offset function to describe the COPD symptoms-time course in patients receiving either triple therapy (n = 907) or dual therapy (n = 894). The IRT improved precision of the estimated drug effect compared to MMRM, resulting in a sample size of at least 3.64 times larger for the MMRM analysis to achieve the IRT precision in the CFB estimate. CONCLUSION: This study shows the advantage of IRT over MMRM with a direct comparison of the same primary endpoint for the two analyses using the same observed clinical trial data, resulting in an increased confidence in Phase III. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11095-022-03194-1. Springer US 2022-03-01 2022 /pmc/articles/PMC9314306/ /pubmed/35233731 http://dx.doi.org/10.1007/s11095-022-03194-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Research Article Llanos-Paez, Carolina Ambery, Claire Yang, Shuying Beerahee, Misba Plan, Elodie L. Karlsson, Mats O. Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients |
title | Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients |
title_full | Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients |
title_fullStr | Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients |
title_full_unstemmed | Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients |
title_short | Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients |
title_sort | improved confidence in a confirmatory stage by application of item-based pharmacometrics model: illustration with a phase iii active comparator-controlled trial in copd patients |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314306/ https://www.ncbi.nlm.nih.gov/pubmed/35233731 http://dx.doi.org/10.1007/s11095-022-03194-1 |
work_keys_str_mv | AT llanospaezcarolina improvedconfidenceinaconfirmatorystagebyapplicationofitembasedpharmacometricsmodelillustrationwithaphaseiiiactivecomparatorcontrolledtrialincopdpatients AT amberyclaire improvedconfidenceinaconfirmatorystagebyapplicationofitembasedpharmacometricsmodelillustrationwithaphaseiiiactivecomparatorcontrolledtrialincopdpatients AT yangshuying improvedconfidenceinaconfirmatorystagebyapplicationofitembasedpharmacometricsmodelillustrationwithaphaseiiiactivecomparatorcontrolledtrialincopdpatients AT beeraheemisba improvedconfidenceinaconfirmatorystagebyapplicationofitembasedpharmacometricsmodelillustrationwithaphaseiiiactivecomparatorcontrolledtrialincopdpatients AT planelodiel improvedconfidenceinaconfirmatorystagebyapplicationofitembasedpharmacometricsmodelillustrationwithaphaseiiiactivecomparatorcontrolledtrialincopdpatients AT karlssonmatso improvedconfidenceinaconfirmatorystagebyapplicationofitembasedpharmacometricsmodelillustrationwithaphaseiiiactivecomparatorcontrolledtrialincopdpatients |